Jerome A. Barakos

Jerome A. Barakos

Auto-generated profile, based on publicly available information

Jerome A. Barakos

California Pacific Medical Center, San Francisco, CA USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
PCP.M. Cogswell
P.M. Cogswell
JBJ.A. Barakos
J.A. Barakos
FBF. Barkhof
F. Barkhof
TBTammie Benzinger
Tammie Benzinger
CJC.R. Jack
C.R. Jack
CWC.T. Whitlow
C.T. Whitlow
SUMMARY: Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities. Amyloid-related imaging abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms. Amyloid-related imaging abnormalities with edema or effusion are transient, treatment-induced edema or sulcal effusion, identified on T2-FLAIR. Amyloid-related imaging abnormalities with hemorrhage are treatment-induced microhemorrhages or superficial siderosis identified on T2* gradient recalled-echo. As monoclonal antibodies become more widely available, treatment screening and monitoring brain MR imaging examinations may greatly increase neuroradiology practice volumes. Radiologists must become familiar with the imaging appearance of amyloid-related imaging abnormalities, how to select an appropriate imaging protocol, and report findings in clinical practice. On the basis of clinical trial literature and expert experience from clinical trial imaging, we summarize imaging findings of amyloid-related imaging abnormalities, describe potential interpretation pitfalls, and provide recommendations for a standardized imaging protocol and an amyloid-related imaging abnormalities reporting template. Standardized imaging and reporting of these findings are important because an amyloid-related imaging abnormalities severity score, derived from the imaging findings, is used along with clinical status to determine patient management and eligibility for continued monoclonal antibody dosing.

1 December 1990 in Gastrointestinal Radiology
Verified
Journal Article
Closed access
PDF file
JBJerome A. Barakos
Jerome A. Barakos
HGHenry I. Goldberg
Henry I. Goldberg
JBJeffrey J. Brown
Jeffrey J. Brown
TGThomas Gilbert
Thomas Gilbert

23 November 2021 in BMC Neurology
Verified
Journal Article
Open access
PDF file
RHR. Matthew Hutchison
R. Matthew Hutchison
KEKarleyton C. Evans
Karleyton C. Evans
TFTara Fox
Tara Fox
MYMinhua Yang
Minhua Yang
JBJerome Barakos
Jerome Barakos
ALAnthony E. Lang
Anthony E. Lang
Background: Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson’s disease (PD). Depending on the stage of progression, approximately 5–15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. Methods: The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. Results: In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). Conclusion: A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects. Trial registration: ClinicalTrials.gov identifier: NCT03318523. Date submitted: October 19, 2017. First Posted: October 24, 2017.

8 December 2022 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
PCP.M. Cogswell
P.M. Cogswell
CJC.R. Jack
C.R. Jack
JBJ.A. Barakos
J.A. Barakos
FBF. Barkhof
F. Barkhof
TBTammie Benzinger
Tammie Benzinger
CWC.T. Whitlow
C.T. Whitlow

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SASusan Abushakra
Susan Abushakra
RMRosalind McLaine
Rosalind McLaine
JBJerome Barakos
Jerome Barakos
APAnton P. Porsteinsson
Anton P. Porsteinsson
DWDavid Watson
David Watson
MTMartin Tolar
Martin Tolar
Background: Plaque clearing amyloid antibodies show an increased risk of amyloid‐related imaging abnormalities with edema or hemorrhages (ARIA‐E or ARIA‐H). ARIA risk increases with number of APOE4 alleles, with APOE4/4 homozygotes showing the highest risk related to high burden of Aβ plaque in microvessels (cerebral amyloid angiopathy, CAA). To decrease the risk of ARIA, amyloid antibody trials exclude subjects with CAA‐related lesions such as >4 microhemorrhages (MH) or superficial siderosis. ALZ‐801 (valiltramiprosate), an oral drug that inhibits formation of neurotoxic Aβ oligomers, shows promising efficacy in APOE4 carriers with no observed ARIA‐E (Abushakra 2017, 2022). Two ALZ‐801 trials are currently ongoing in APOE4 carriers with Early AD. A Phase 2 study enrolled APOE4 carriers, and a Phase 3 trial enrolled APOE4/4 patients. Both studies allow >10 MH and/or some siderosis lesions at baseline.Method: The fully‐enrolled Phase 3 trial (APOLLOE4) included 325 homozygotes with Early AD (MMSE ≥22). We evaluated prevalence of microhemorrhages (MH), macrohemorrhages and superificial siderosis (CAA lesions). Baseline MRIs acquired from 1.5T/3T scanners were centrally evaluated by Clario, and the number/location of these CAA lesions is reported.Result: Subjects had mean age 69 years, 51% female, MMSE 26, 82% white, 65% with MCI. Of 325 subjects, 313 had baseline MRIs that showed > 1 MH in 32%, including 9% with > 4 MH. A total of 9% had ≥ 1 superficial siderosis, and 2 subjects had macrohemorrahages. Occipital and frontal lobes were most common locations of CAA lesions. Most subjects had white matter disease (Fazekas = 1).Conclusion: APOE4/4 homozygotes show high prevalence of CAA lesions with 32% and 9% having lobar microhemorrhages and superificial siderosis respectively. This high burden of CAA lesions most likely underlies the high incidence of ARIA in APOE4/4 patients treated with the approved amyloid antibodies (30%‐60%). ARIA‐E is also reported in APOE4/4 patients treated with placebo in lecanemab & gantenerumab trials (4%‐6%). This background ARIA likely reflects spontaneous CAA‐related inflammation commonly reported in APOE4 carriers (CAA‐RI, Regendhardt 2020). Oral ALZ‐801 in the ongoing studies has not shown increased ARIA risk, and has safety advantage over amyloid antibodies especially for APOE4/4 homozygous patients.